搡老女人多毛老妇女中国,日韩亚洲欧美中文高清在线,人妻少妇一区二区三区,色妞色综合久久夜夜,日本熟妇xxxx

Your Good Partner in Biology Research

Human Breast and kidney expressed chemokine,BRAK ELISA Kit

  • 中文名稱:
    人胸腎表達(dá)趨化因子(BRAK/CXCL14)酶聯(lián)免疫試劑盒
  • 貨號(hào):
    CSB-E10025h
  • 規(guī)格:
    96T/48T
  • 價(jià)格:
    ¥3600/¥2500
  • 其他:

產(chǎn)品詳情

  • 產(chǎn)品描述:
    人胸腎表達(dá)趨化因子(BRAK/CXCL14)酶聯(lián)免疫試劑盒(CSB-E10025h)為雙抗夾心法ELISA試劑盒,定量檢測血清、血漿、組織勻漿樣本中的CXCL14含量。CXCL14是重要靶點(diǎn)。其在多種生理和病理過程中發(fā)揮作用,在免疫調(diào)節(jié)、炎癥反應(yīng)等方面背景關(guān)鍵。研究機(jī)制上,它主要通過與相應(yīng)受體結(jié)合,調(diào)控細(xì)胞的遷移、增殖等行為,對(duì)其深入研究有助于開發(fā)相關(guān)疾病的治療方法。試劑盒檢測范圍為0.39 ng/ml-25 ng/ml.,靈敏度為0.09 ng/ml.。適用于體外實(shí)驗(yàn)中對(duì)不同來源樣本的BRAK/CXCL14蛋白表達(dá)量分析,可滿足基礎(chǔ)科研領(lǐng)域如免疫學(xué)、腫瘤生物學(xué)、分子病理學(xué)等研究方向的需求,為探索該靶點(diǎn)在細(xì)胞信號(hào)傳導(dǎo)、組織微環(huán)境互作中的功能提供可靠工具本品僅用于科研,不用于臨床診斷,產(chǎn)品具體參數(shù)及操作步驟詳見產(chǎn)品說明書。
  • 別名:
    1110031L23Rik ELISA Kit; 1200006I23Rik ELISA Kit; AI414372 ELISA Kit; BMAC ELISA Kit; bolekine ELISA Kit; BRAK ELISA Kit; Breast and kidney ELISA Kit; C-X-C motif chemokine 14 ELISA Kit; C-X-C motif chemokine ligand 14 ELISA Kit; Chaemokine; CXC motif; ligand 14 ELISA Kit; Chemokine (C-X-C motif) ligand 14 ELISA Kit; Chemokine BRAK ELISA Kit; CXC chemokine in breast and kidney ELISA Kit; CXCL14 ELISA Kit; CXL14_HUMAN ELISA Kit; JSC ELISA Kit; Kec ELISA Kit; Kidney-expressed chemokine CXC ELISA Kit; KS1 ELISA Kit; MGC10687 ELISA Kit; MGC124510 ELISA Kit; MGC90667 ELISA Kit; MIP 2 gamma ELISA Kit; MIP-2G ELISA Kit; MIP2G ELISA Kit; MIP2gamma ELISA Kit; NJAC ELISA Kit; PRO273 ELISA Kit; PSEC0212 ELISA Kit; Scyb14 ELISA Kit; Small Inducible Cytokine B14 ELISA Kit; Small inducible cytokine subfamily B (Cys-X-Cys) member 14 (BRAK) ELISA Kit; Small Inducible Cytokine subfamily B; member 14 ELISA Kit; Small-inducible cytokine B14 ELISA Kit; Tumor suppressing chemokine ELISA Kit; UNQ240 ELISA Kit
  • 縮寫:
  • Uniprot No.:
  • 種屬:
    Homo sapiens (Human)
  • 樣本類型:
    serum, plasma, tissue homogenates
  • 檢測范圍:
    0.39 ng/ml-25 ng/ml.
  • 靈敏度:
    0.09 ng/ml.
  • 反應(yīng)時(shí)間:
    1-5h
  • 樣本體積:
    50-100ul
  • 檢測波長:
    450 nm
  • 研究領(lǐng)域:
    Immunology
  • 測定原理:
    quantitative
  • 測定方法:
    Sandwich
  • 精密度:

    Intra-assay Precision (Precision within an assay): CV%<8%

    Three samples of known concentration were tested twenty times on one plate to assess.

    Inter-assay Precision (Precision between assays): CV%<10%

    Three samples of known concentration were tested in twenty assays to assess.

  • 線性度:

    To assess the linearity of the assay, samples were spiked with high concentrations of human BRAK/CXCL14 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.

     

    Sample

    Serum(n=4)

    1:1

    Average %

    94

    Range %

    88-100

    1:2

    Average %

    95

    Range %

    90-101

    1:4

    Average %

    98

    Range %

    92-105

    1:8

    Average %

    93

    Range %

    86-99

  • 回收率:

    The recovery of human BRAK/CXCL14 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.

    Sample Type

    Average % Recovery

    Range

    Serum (n=5)

    95

    89-98

    EDTA plasma (n=4)

    97

    90-110

  • 標(biāo)準(zhǔn)曲線:

    These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.

    ng/ml

    OD1

    OD2

    Average

    Corrected

    25

    3.056

    2.934

    2.995

    2.828

    12.5

    1.622

    1.667

    1.644

    1.477

    6.25

    1.055

    1.028

    1.041

    0.874

    3.12

    0.656

    0.629

    0.643

    0.475

    1.56

    0.454

    0.471

    0.462

    0.295

    0.78

    0.247

    0.253

    0.250

    0.083

    0.39

    0.191

    0.184

    0.187

    0.020

    0

    0.170

    0.165

    0.167

     

  • 數(shù)據(jù)處理:
  • 貨期:
    3-5 working days

產(chǎn)品評(píng)價(jià)

靶點(diǎn)詳情

  • 功能:
    Potent chemoattractant for neutrophils, and weaker for dendritic cells. Not chemotactic for T-cells, B-cells, monocytes, natural killer cells or granulocytes. Does not inhibit proliferation of myeloid progenitors in colony formation assays.
  • 基因功能參考文獻(xiàn):
    1. These findings indicate that CXCL14 is a critical immunomodulator involved in the stroke-induced inflammatory reaction. PMID: 28382159
    2. High CXCL14 expression is associated with metastatic progression of Ovarian Cancer. PMID: 28087599
    3. These results suggest that CXCL14 downregulation by human papillomaviruses plays an important role in suppression of antitumor immune responses. PMID: 27143385
    4. Platelets are a relevant source of CXCL14. Platelet-derived CXCL14 at the site of vascular lesions might play an important role in vascular repair/regeneration. PMID: 28359053
    5. Epithelial CXCL14 expression is significantly associated with ERalpha positivity and low proliferation, whereas stromal CXCL14 expression is not linked to any of the established clinicopathological parameters, subtypes of breast cancer or tumour stroma abundance. PMID: 27115465
    6. Elevated expression of CXCL14 in osteosarcoma tissues correlated with poor prognosis of the osteosarcoma patients. PMID: 27259322
    7. Elevated S100A6 enhances tumorigenesis and suppresses CXCL14-induced apoptosis in clear cell renal cell carcinoma. PMID: 25760073
    8. three of these five genes (CXCL14, ITGAX, and LPCAT2) harbored polymorphisms associated with aggressive disease development in a human GWAS cohort consisting of 1,172 prostate cancer patients. PMID: 25411967
    9. Prometastatic effects of IRX1 were mediated by upregulation of CXCL14/NF-kappaB signaling. PMID: 25822025
    10. CXCL14 overexpression influences proliferation and changes in cell cycle distributions of HT29 colorectal carcinoma cells. PMID: 24938992
    11. Data indicate that site-specific CpG methylation in the CXC chemokine CXCL14 promoter is associated with altered expression. PMID: 25102097
    12. CXCL14 displays antimicrobial activity against E. coli and S. aureus. PMID: 12949249
    13. Genetic or pharmacologic inhibition of NOS1 reduced the growth of CXCL14-expressing fibroblasts. PMID: 24710408
    14. CXCL14 inhibits colorectal cancer migration, invasion, and epithelial-to-mesenchymal transition (EMT) by suppressing NF-kappaB signaling. PMID: 24099668
    15. Downregulation of CXCL14 expression is associated with gastric adenocarcinoma. PMID: 23982764
    16. CXCL14 plays a pivotal role as a potential tumor suppressor in hepatocellular carcinoma. PMID: 24033560
    17. Smoking-induced CXCL14 expression in the human airway epithelium links chronic obstructive pulmonary disease to lung cancer. PMID: 23597004
    18. CXCL14 binding to glycoproteins harboring heparan sulfate proteoglycans and sialic acids leads proliferation and migration of some cancer cells. PMID: 23161284
    19. CXCL14 might be a potential novel prognostic factor to predict the disease recurrence and overall survival and could be a potential target of postoperative adjuvant therapy in CRC patients PMID: 23294544
    20. CXCL14 is a negative regulator of growth and metastasis in breast cancer. PMID: 22910931
    21. These results indicated that upregulation of BRAK was accompanied by differentiation of epithelial cells induced by calcium/calmodulin signaling, and that SP1 binding to the BRAK promoter region played an important role in this signaling. PMID: 22382027
    22. The rs2237062 polymorphism in the CXCL14 gene might influence Hepatits B Virus-related hepatocellular carcinoma progression in a Chinese population. PMID: 21556757
    23. CEACAM-1 and CXCL-14 are involved in the occurrence and development of infantile hemangioma. PMID: 20737948
    24. The results indicate that oxidative stress induced by H(2)O(2) or HO(*) stimulates angiogenesis and tumuor progression by altering the gene expression of CXCL14 via the EGFR/MEK/ERK pathway in human HNSCC cells. PMID: 20815772
    25. Data indicate that the expression of BRAK stimulated the formation of elongated focal adhesions of the HSC-3 cells in an autocrine or paracrine fashion, in which stimulation may be responsible for the reduced migration of the cells. PMID: 20067447
    26. CXCL14 methylation in sputum from asymptomatic early-stage lung cancer cases was associated with a 2.9-fold elevated risk for this disease compared with controls, substantiating its potential as a biomarker for early detection of lung cancer PMID: 20562917
    27. Taken together, the data indicate that the respective stress-dependent action of p38 isoforms is responsible for the up-regulation of the gene expression of the chemokine BRAK/CXCL14. PMID: 20478268
    28. CXCL14 removal from conditioned media abolished its chemotactic properties. Findings offer direct evidence for epigenetic regulation of chemokine expression in tumor cells. PMID: 20460540
    29. Increased severity of collagen-induced arthritis in CXCL14-transgenic mice is associated with enhanced T helper (Th) type 1 cytokine production, elevated autoantibody levels and increased inflammatory cell infiltration into the joints. PMID: 20212097
    30. Data conclude that CXCL14 is likely to be regulated by progesterone in human endometrium and that it may exert a chemoattractive effect on uNK cells and in part be responsible for their clustering around the epithelial glands. PMID: 19903701
    31. Results suggest that CXCL14 plays an important role in regulating trophoblast invasion through an autocrine/paracrine manner during early pregnancy. PMID: 19833716
    32. loss of BRAK expression from tumors may facilitate neovascularization and possibly contributes to immunologic escape PMID: 15548693
    33. The finding that CXCL14 expression inhibits prostate tumor growth suggests this gene has tumor suppressive functions. PMID: 15651028
    34. CXCL14 is a potent chemoattractant and activator of dendritic cells (DC) and may be involved in DC homing in vivo. PMID: 15843547
    35. results indicate that BRAK/CXCL14 is a chemokine, having suppressive activity toward tumor progression of oral carcinoma in vivo PMID: 16884687
    36. This study elucidates a post-translational mechanism for the loss of CXCL14 in cancer and a novel mode of chemokine regulation. PMID: 16987528
    37. CXCL14 might play a pivotal role in the pathobiology of pancreatic cancer, probably by regulating cancer invasion. PMID: 18054154
    38. CXCL14 is a gene target of RhoBTB2 and supports downregulation of CXCL14 as a functional outcome of RhoBTB2 loss in cancer. PMID: 18762809
    39. CXCL14-positive epithelial cells were found in all tissue types. The expression of CXCL14 was not associated with any tumor or patient characteristics analyzed PMID: 18765527
    40. Data suggest that despite the structural homology and similarity in tissue distribution of human and murine CXCL14, distinct differences point to diverse, species-specific needs for CXCL14 in epithelial immunity. PMID: 18809336
    41. Cell supernatant-derived CXCL14 fights bacteria at the earliest stage of infection, well before the establishment of inflammation, and thus fulfills a unique role in antimicrobial immunity. PMID: 19109182
    42. regulates energy metabolism and eating behaviior, induces insulin resistance, suppresses induction of neovascularization. (review) PMID: 19172796
    43. identify CXCL14 as a novel autocrine stimulator of fibroblast growth and migration, with multi-modal tumor-stimulatory activities PMID: 19218429
    44. CXCL14 expression is upregulated by ROS through the AP-1 signaling pathway and promotes cell motility through elevation of cytosolic Ca(2+) by binding to the inositol 1,4,5-trisphosphate receptor on the endoplasmic reticulum in breast cancer. PMID: 19276362
    45. -A-induced migration depends on the selective and polarized release of 2 chemokines, namely CXC chemokine ligands 12 and 14 PMID: 19339694

    顯示更多

    收起更多

  • 亞細(xì)胞定位:
    Secreted.
  • 蛋白家族:
    Intercrine alpha (chemokine CxC) family
  • 組織特異性:
    Expressed in heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas. Highly expressed in normal tissue without inflammatory stimuli and infrequently expressed in cancer cell lines. Weakly expressed in monocyte-derived dendritic cells. N
  • 數(shù)據(jù)庫鏈接:

    HGNC: 10640

    OMIM: 604186

    KEGG: hsa:9547

    STRING: 9606.ENSP00000337065

    UniGene: Hs.483444